ArticleFrontiers in neurology2021
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.Neurology and therapy · 2026Review
- Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.Neurodegenerative disease management · 2025Article
- Real-World Perspectives on Switching Patients with Multiple Sclerosis from Anti-CD20 Therapy to Cladribine Tablets from USA-Based Advanced Practice Providers: A Podcast.Advances in therapy · 2025Article
- From youth to late age: a comparative analysis of clinical and demographic profiles in multiple sclerosis by age at onset.Postepy psychiatrii neurologii · 2025Article
- Local control of T cell fate in lymph nodes safely and durably reverses myelin-driven autoimmunity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.Journal of neurology · 2025Review
- Integrating big data and artificial intelligence to predict progression in multiple sclerosis: challenges and the path forward.Journal of neuroengineering and rehabilitation · 2025Review
- Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study.Neurology and therapy · 2025Article
- Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: a single center, retrospective, observational study.Frontiers in neurology · 2025Article
- Real-world use of disease-modifying therapy in persons with multiple sclerosis aged 55 and over.BMJ neurology open · 2025Article
- Real-world persistence of multiple sclerosis disease-modifying therapies.European journal of neurology · 2024Article
- Big Multiple Sclerosis Data network: an international registry research network.Journal of neurology · 2024Article
- Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.Journal of neurology · 2024Article
- Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.Journal of central nervous system disease · 2024Article
- Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.Therapeutic advances in neurological disorders · 2024Article
- Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany.Therapeutic advances in neurological disorders · 2024Article
- The arisal of data spaces: why I am excited and worried.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.